bpc-157 fda statement not approved for human use FDA's Overreach on Compounded Peptides BPC-157 aka Wolverine. This peptide
Description
References 1 AglerH
(d) review articles or non-clinical studies
In 2023 the FDA placed CJC-1295 in "Category 2" of its interim 503A bulks list, meaning it identified significant safety concerns and did not permit its use in traditional pharmacy compounding

You will receive a certificate of completion with continuing medical education credits recognized by major medical boards and credentialing organizations
